About

Management Team

Lei Xiao, Ph.D.

Lei Xiao, Ph.D.

CSO, Chairman, Chief Executive Officer

Over 15 years' experience studying CAR-T, stem cells and cell therapy.

Served as Professor and Doctoral supervisor at Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences of CAS, and Zhejiang University.

Completed postdoctoral training at The Johns Hopkins University; holds a Ph.D. from Ludwig-Maximilians Universität München.

10-year tenure in biotech R&D, Winner of The National Science Fund for Distinguished Young Scholars; member of "Shanghai 1,000 Talents Plan"; expert group member of "Major Research Programs in Stem Cells" sponsored by Ministry of Science and Technology of the P.R.C.

Zhao Wu, Ph. D.

Zhao Wu, Ph. D.

President

Over 10 years of research experience in stem cells and cell therapy. Holds a Ph.D. from the Institute of Biochemistry and Cell Biology, CAS, and a B.A. from Xiamen University.

Initially established human iPS cell line, established porcine iPS cell line and human embryonic stem cells. Her thesis was published in an international journal and has been cited over 300 times.

9-year development leadership roles in biotech industry in China, Member of the "Shanghai Scientific & Technological New Youth Stars Program"; awarded the Shanghai Municipal Labor Medal.

Le Tian, Ph.D.

Le Tian, Ph.D.

Senior Vice President, General Counsel

Completed postdoctoral training at University of Washington School of Medicine; holds a Ph.D. from the University of Texas at Austin & J.D. from University of Washington School of Law.

10-years Intellectual Property preparation and prosecution experiences in life sciences for bio-tech and pharmaceutic companies, conducted licensing, pre-licensing and technology transfer diligence on intercultural properties.

Brad Fackler

Brad Fackler

Senior Vice President, Operations and Business Development

Over 35 years of experience in the pharmaceutical and biotech industries.

Held senior leadership positions with Novartis Pharmaceuticals, Sucampo Pharmaceuticals and Cellona Therapeutics; as well as the Office of BioHealth and Life Sciences for the Maryland Department of Commerce.

Earned a B.A. in Biology from Otterbein University and an M.B.A. from the Leonard Stern School of Business at New York University.

Xiaobin Victor Lu, Ph.D.

Xiaobin Victor Lu, Ph.D.

Senior VP, Head of Regulatory Affairs

Over 18 years’ experience in product development and regulatory affairs for cellular and gene therapies.

10 years’ experience as a Reviewer of U.S. FDA in the Gene Therapy Branch, Division of Cellular and Gene Therapies, Office of Tissue and Advanced Therapies, Center for Biologics Evaluation and Research, with the main role of reviewing applications for cellular and gene therapy based investigational new drug (INDs) products and biologics license applications (BLAs) including CAR-T cells.

7 years’ R & D experience as a Senior Director at VIRxSYS Corporation overseeing the first lentiviral vector-based gene therapy investigational product in human clinical trials.

Completed postdoctoral training at the University of California, San Francisco (UCSF) and holds a Ph.D. from State University of New York at Buffalo in Molecular Virology.

Timothy Mitchell

Timothy Mitchell

Vice President, Quality Assurance and Compliance

Extensive experience within the human cell therapy, biologics, and pharmaceutical industries, focusing mainly in the areas of quality assurance & control, global compliance, validation, regulatory affairs, engineering, site management, and manufacturing operations.

Held senior leadership positions with Endocyte (a Novartis company), Celgene Corporation, Eli Lilly, and other companies.

Earned a B.S. in both Genetic Biology and Biochemistry from Purdue University.

Scientific Collaboration

ICT Bio Scientific Collaborations